{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"description":"Number of participants with serious adverse events or dose limiting toxicities related to the study intervention assessed using Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria.","groups":[{"description":"Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).\n\nArtesunate Suppositories","id":"OG000","title":"50 mg Artesunate Suppositories, 1 Cycle"},{"description":"Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).\n\nArtesunate Suppositories","id":"OG001","title":"200 mg Artesunate Suppositories, 1 Cycle"},{"description":"Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).\n\nArtesunate Suppositories","id":"OG002","title":"200 mg Artesunate Suppositories,2 Cycles"},{"description":"Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).\n\nArtesunate Suppositories","id":"OG003","title":"200 mg Artesunate Suppositories,3 Cycles"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"41 weeks","title":"Number of Participants With Serious Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}